Literature DB >> 18984170

Rosiglitazone no longer recommended.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18984170     DOI： 10.1016/S0140-6736(08)61628-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.

Authors:  Federica Gilardi; Marco Giudici; Nico Mitro; Omar Maschi; Uliano Guerrini; Gianpaolo Rando; Adriana Maggi; Gaia Cermenati; Antonio Laghezza; Fulvio Loiodice; Giorgio Pochetti; Antonio Lavecchia; Donatella Caruso; Emma De Fabiani; Krister Bamberg; Maurizio Crestani
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

2.  Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.

Authors:  Richard L Morrow; Greg Carney; James M Wright; Ken Bassett; Jenny Sutherland; Colin R Dormuth
Journal:  Open Med       Date:  2010-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.